Happy eclipse day. There is little news both in the sector and in the market. This is not necessarily a bad thing as it might give us a sense as.
Everyone in the world knows that there’s a huge Alzheimer’s catalyst coming up for AXON. As such, the options are priced pretty crazy. October options are priced as if $50.
There is nothing to dissuade me that risk on is creeping back into the market as North Korea is fading into the background (for how long who knows but that.
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.
The recovery continues as risk-on seems to be heading back into the market. Part of me sees this as what I expected in terms of a sell off to test.
The macro risks are helping to bring down the sector and we are just about at those breakout levels that I have been talking about. Of course, I also noted.
Another day with some news and catch up. The sector is still not doing well as we see positive individual moves that seem to have no read through other stocks..
I am back from my last trip of the summer and to be honest it is going to take me the weekend to catch up on all the news. That.
If there has been a consistent theme to earnings this week it has been beat and raise but with stock underperformance. This is not great in the near term as.
Dave Trading – August 2017 *** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued,.
The sector got a big boost from VRTX last night. If it cannot rally off of this news, then buckle your seatbelts and hedge your positions as there is unlikely.
A little bit of news to start the week but nothing dramatic and still none of the M&A that was supposed to explode this year leading the recovery of the.
We have some news and perhaps additional news but unconfirmed as of yet. In general, however, the sector seems to be more or less treading water without a real upside.
We are getting some news at least but nothing that is thesis changing but perhaps just enough to move the needle for the sector but that is to be determined..
The sector seems to be consolidating its previous move although the broader market does not necessarily look that strong. That being said the trend for the sector is higher and.
We are finally getting a break in the move higher but it has been quiet impressive. There was less excitement in the move than I would have thought, which I.
Biotech is clearly back. We appear to be breaking out of the range with perhaps broadening participation and increasing volume. I am not a technician but this is looking good..